D J Rabbolini1, M-C Morel-Kopp1, Q Chen1, S Gabrielli1, L C Dunlop2, L P Chew3, N Blair4, T A Brighton5, N Singh6, A P Ng7,8, C M Ward1, W S Stevenson1. 1. Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia. 2. Department of Haematology, Liverpool Hospital, Sydney, Australia. 3. Department of Haematology, Sarawak General Hospital, Sarawak, Malaysia. 4. Department of Neurogenetics, The Royal North Shore Hospital, Sydney, Australia. 5. Department of Haematology, Prince of Wales Hospital, Sydney, Australia. 6. Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, Australia. 7. Department of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. 8. Department of Medical Biology, The University of Melbourne, Melbourne, Australia.
Abstract
Essentials The phenotypes of different growth factor-independent 1B (GFI1B) variants are not established. GFI1B variants produce heterogeneous clinical phenotypes dependent on the site of mutation. Mutation of the first non-DNA-binding zinc-finger causes a mild platelet and clinical phenotype. GFI1B regulates the CD34 promoter; platelet CD34 expression is an indicator of GFI1B mutation. SUMMARY: Background Mutation of the growth factor-independent 1B (GFI1B) fifth DNA-binding zinc-finger domain causes macrothrombocytopenia and α-granule deficiency leading to clinical bleeding. The phenotypes associated with GFI1B variants disrupting non-DNA-binding zinc-fingers remain uncharacterized. Objectives To determine the functional and phenotypic consequences of GFI1B variants disrupting non-DNA-binding zinc-finger domains. Methods The GFI1B C168F variant and a novel GFI1B c.2520 + 1_2520 + 8delGTGGGCAC splice variant were identified in four unrelated families. Phenotypic features, DNA-binding properties and transcriptional effects were determined and compared with those in individuals with a GFI1B H294 fs mutation of the fifth DNA-binding zinc-finger. Patient-specific induced pluripotent stem cell (iPSC)-derived megakaryocytes were generated to facilitate disease modeling. Results The DNA-binding GFI1B variant C168F, which is predicted to disrupt the first non-DNA-binding zinc-finger domain, is associated with macrothrombocytopenia without α-granule deficiency or bleeding symptoms. A GFI1B splice variant, c.2520 + 1_2520 + 8delGTGGGCAC, which generates a short GFI1B isoform that lacks non-DNA-binding zinc-fingers 1 and 2, is associated with increased platelet CD34 expression only, without quantitative or morphologic platelet abnormalities. GFI1B represses the CD34 promoter, and this repression is attenuated by different GFI1B zinc-finger mutations, suggesting that deregulation of CD34 expression occurs at a direct transcriptional level. Patient-specific iPSC-derived megakaryocytes phenocopy these observations. Conclusions Disruption of GFI1B non-DNA-binding zinc-finger 1 is associated with mild to moderate thrombocytopenia without α-granule deficiency or bleeding symptomatology, indicating that the site of GFI1B mutation has important phenotypic implications. Platelet CD34 expression appears to be a common feature of perturbed GFI1B function, and may have diagnostic utility.
Essentials The phenotypes of different growth factor-independent 1B (GFI1B) variants are not established. GFI1B variants produce heterogeneous clinical phenotypes dependent on the site of mutation. Mutation of the first non-DNA-binding zinc-finger causes a mild platelet and clinical phenotype. GFI1B regulates the CD34 promoter; platelet CD34 expression is an indicator of GFI1B mutation. SUMMARY: Background Mutation of the growth factor-independent 1B (GFI1B) fifth DNA-binding zinc-finger domain causes macrothrombocytopenia and α-granule deficiency leading to clinical bleeding. The phenotypes associated with GFI1B variants disrupting non-DNA-binding zinc-fingers remain uncharacterized. Objectives To determine the functional and phenotypic consequences of GFI1B variants disrupting non-DNA-binding zinc-finger domains. Methods The GFI1BC168F variant and a novel GFI1Bc.2520 + 1_2520 + 8delGTGGGCAC splice variant were identified in four unrelated families. Phenotypic features, DNA-binding properties and transcriptional effects were determined and compared with those in individuals with a GFI1BH294 fs mutation of the fifth DNA-binding zinc-finger. Patient-specific induced pluripotent stem cell (iPSC)-derived megakaryocytes were generated to facilitate disease modeling. Results The DNA-binding GFI1B variant C168F, which is predicted to disrupt the first non-DNA-binding zinc-finger domain, is associated with macrothrombocytopenia without α-granule deficiency or bleeding symptoms. A GFI1B splice variant, c.2520 + 1_2520 + 8delGTGGGCAC, which generates a short GFI1B isoform that lacks non-DNA-binding zinc-fingers 1 and 2, is associated with increased platelet CD34 expression only, without quantitative or morphologic platelet abnormalities. GFI1B represses the CD34 promoter, and this repression is attenuated by different GFI1B zinc-finger mutations, suggesting that deregulation of CD34 expression occurs at a direct transcriptional level. Patient-specific iPSC-derived megakaryocytes phenocopy these observations. Conclusions Disruption of GFI1B non-DNA-binding zinc-finger 1 is associated with mild to moderate thrombocytopenia without α-granule deficiency or bleeding symptomatology, indicating that the site of GFI1B mutation has important phenotypic implications. Platelet CD34 expression appears to be a common feature of perturbed GFI1B function, and may have diagnostic utility.
Authors: Rinske van Oorschot; Anna E Marneth; Saskia M Bergevoet; Maaike G J M van Bergen; Kathelijne Peerlinck; Claire E Lentaigne; Carolyn M Millar; Sarah K Westbury; Remi Favier; Wendy N Erber; Ernest Turro; Joop H Jansen; Willem H Ouwehand; Harriet L McKinney; Kate Downes; Kathleen Freson; Bert A van der Reijden Journal: Haematologica Date: 2018-12-20 Impact factor: 9.941
Authors: Maaike G J M van Bergen; Joline L Saes; Annet Simons; Konnie M Hebeda; Yvonne M C Henskens; Wideke Barteling; Erik Huys; Britta A P Laros-van Gorkom; Saskia E M Schols; Frank W Preijers; Marjolijn C J Jongmans; Joop H Jansen; Bert A van der Reijden Journal: Am J Hematol Date: 2020-04-08 Impact factor: 10.047
Authors: Rinske van Oorschot; Marten Hansen; Johanna M Koornneef; Anna E Marneth; Saskia M Bergevoet; Maaike G J M van Bergen; Floris P J van Alphen; Carmen van der Zwaan; Joost H A Martens; Michiel Vermeulen; Pascal W T C Jansen; Marijke P A Baltissen; Britta A P Laros-van Gorkom; Hans Janssen; Joop H Jansen; Marieke von Lindern; Alexander B Meijer; Emile van den Akker; Bert A van der Reijden Journal: Haematologica Date: 2019-01-17 Impact factor: 9.941
Authors: Ben Johnson; Rachel Doak; David Allsup; Emma Astwood; Gillian Evans; Charlotte Grimley; Beki James; Bethan Myers; Simone Stokley; Jecko Thachil; Jonathan Wilde; Mike Williams; Mike Makris; Gillian C Lowe; Yvonne Wallis; Martina E Daly; Neil V Morgan Journal: Res Pract Thromb Haemost Date: 2018-10-08